NCT05363280
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05363280
Title Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Advenchen Pharmaceuticals, LLC.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ESP


No variant requirements are available.